VolitionRx Limited, a multinational epigenetics company trading on the NYSE American under VNRX, has released results from a clinical study indicating its Nu.Q Vet Feline assay can accurately detect lymphoma in cats. The blood-based test demonstrated the ability to detect more than 80% of feline lymphomas with 100% specificity, meaning it produced no false positives in the study. Lymphoma is the most common cancer diagnosed in cats.
The company stated that diagnosing cancer in cats has historically been challenging, often requiring invasive biopsies or expensive imaging procedures, typically only pursued after symptoms have become apparent. Veterinarians have long sought a reliable screening tool for feline cancers. This development follows the international rollout of the company's canine cancer test, suggesting the underlying epigenetic technology platform is effective across species. VolitionRx plans to complete product development and make the Nu.Q Vet Feline Test available through existing distribution channels, including reference laboratories and point-of-care platforms.
The importance of this advancement lies in the potential for earlier and less invasive detection of a prevalent and serious disease. Early detection can significantly impact treatment options and outcomes for affected animals. For the veterinary industry, a simple, affordable blood test could become a standard part of wellness checks, shifting cancer diagnosis from a reactive to a more proactive process. This aligns with VolitionRx's broader corporate mission, as detailed on its website https://volition.com/, which is focused on saving lives and improving outcomes through earlier detection of life-altering diseases.
The full details of the announcement were published in a press release available online. The news was distributed by BioMedWire, a specialized communications platform within the IBN network that focuses on biotechnology and life sciences sectors. More information about BioMedWire's services and disclaimers can be found at https://www.BioMedWire.com and https://www.BioMedWire.com/Disclaimer. The implications extend beyond animal health, as successful application in veterinary medicine can further validate the company's epigenetic technology for potential future human health applications.
